Clinical Trial Update: REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 [Phase 2, Phase 3]

View source ↗

Summary

The REFRaME-O1 trial evaluating Luveltamab Tazevibulin versus investigator's choice chemotherapy for FOLR1-expressing ovarian cancer and related peritoneal canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Luveltamab Tazevibulin

Snippet

Sponsor: Sutro Biopharma, Inc. | Conditions: Ovarian Cancer, Epithelial Ovarian Cancer | Phase 2, Phase 3 | Status: TERMINATED